STOCK TITAN

Revive Therapeutics Ltd - RVVTF STOCK NEWS

Welcome to our dedicated news page for Revive Therapeutics (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revive Therapeutics's position in the market.

Rhea-AI Summary
Revive Therapeutics Ltd. (RVVTF) has signed a collaboration agreement with Attwill Medical Solutions LP for the clinical and commercial development of its next-generation lyophilized formulation of Bucillamine. The collaboration aims to support the technology transfer of the formulation from the University of Waterloo to AMS, with expectations of clinical evaluation in 2024. The novel lyophilized Bucillamine may have potential applications in treating nerve agent exposure and rare inflammatory disorders, with the FDA granting orphan drug designation for ischemia-reperfusion injury in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
-
Rhea-AI Summary
Revive Therapeutics (RVVTF) provides an update on the development of a next generation lyophilized formulation of Bucillamine, expected to be completed by the end of the year. The research team has improved the solubility of Bucillamine, resulting in more than double enhancement of solubility, unlocking therapeutic utility for public health medical emergencies. The novel formulation could support the continuation of the research project with the Canadian Department of National Defence. The Company expects to have its novel lyophilized formulation of Bucillamine ready for production for clinical evaluation in 2024, potentially helping rare inflammatory disorders such as ischemia-reperfusion injury, for which the FDA granted orphan drug designation in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Revive Diagnostics Inc., a subsidiary of Revive Therapeutics, has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID. The biomarkers were discovered by a research team at Lawson and may help in the correct diagnosis and treatment of long COVID, which affects at least 10% of severe COVID-19 cases. Revive Diagnostics will develop a qELISA laboratory test kit and a lateral flow assay point of care device for rapid testing of long COVID. They will also explore the potential of the long COVID test as a companion to Bucillamine, a potential treatment for the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
covid-19
Rhea-AI Summary
Revive Therapeutics announces agreement with Defence R&D Canada to evaluate Bucillamine as a treatment for nerve agent exposure
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
Rhea-AI Summary
Revive Therapeutics provides update on development of next generation lyophilized formulation of Bucillamine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Summary
Revive Therapeutics initiates development of next generation formulation of Bucillamine for potential treatment of public health emergencies and rare inflammatory disorders. Company enters sponsored research agreement with University of Waterloo. Formulation development expected by end-2023. Strategic initiatives include targeting rare disorders, seeking pharmaceutical partnerships, and government support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.52%
Tags
none
-
Rhea-AI Summary
Revive Therapeutics announces results of Phase 3 clinical trial for oral Bucillamine in COVID-19 patients. Study did not achieve statistical significance on clinical endpoints. No deaths, four hospitalizations. Positive trend observed in post-dose selection phase. Further analysis ongoing. Company committed to advancing development of Bucillamine and pursuing strategic initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Revive Therapeutics provides an update on the FDA Phase 3 clinical trial for Bucillamine in COVID-19 patients. The study has been halted and the company is evaluating the data to support future discussions with the FDA and potential new clinical studies. Revive Therapeutics plans to continue discussions with the FDA, work with pharmaceutical partners for regulatory approvals, and evaluate drug development strategies for Bucillamine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.64%
Tags
clinical trial covid-19
Revive Therapeutics Ltd

OTC:RVVTF

RVVTF Rankings

RVVTF Stock Data

7.17M
353.21M
1.46%
0.04%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Woodbridge